Drug Trial Radar · NCT07333469
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jan 19, 2026
Primary completion
Jan 19, 2028
Study completion Jan 19, 2030
Sponsor
- Lead sponsor
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the preliminary antitumor activity of HX111.
Conditions
- Solid Tumor and Lymphoma
Interventions
HX111 for injectionDrug
HX111, 0.5-2.5mg/kg, once every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTsTime frame: 21 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.